Literature DB >> 14592536

Distinct role and functional mode of TR3 and RARalpha in mediating ATRA-induced signalling pathway in breast and gastric cancer cells.

Xiao feng Ye1, Qiao Wu, Su Liu, Xiao feng Lin, Bing Zhang, Jia fa Wu, Jian huai Cai, Ming qing Zhang, Wen jin Su.   

Abstract

All-trans retinoic acid (ATRA) affects cell proliferation, differentiation and apoptosis through its receptors, RARs and RXRs. Besides these, other receptors such as orphan receptor TR3, are also involved in the regulatory process of ATRA. However, how different receptors function in response to ATRA is still largely unknown. In the present study, we found that formation of TR3/RXRalpha heterodimers in the nucleus and their subsequent translocation into the cytoplasm, in association with regulation of apoptosis-related proteins Bcl-2, Bcl-xl and Bax, was critical for apoptosis induction by ATRA in breast cancer cells MCF-7. When such translocation was blocked by Leptomycin B (LMB), ATRA-induced apoptosis was consequently abolished. However, in ATRA-induced gastric cancer cells MGC80-3, RXRalpha heterodimerised with RARalpha but not with TR3, and remained in the nucleus exerting its effect on cell cycle regulation. When transfected with antisense-RARalpha, MGC80-3 cells changed from ATRA-sensitive to ATRA-resistant and most cells were arrested in the S phase, implying the importance of RARalpha in cell cycle regulation. Furthermore, we demonstrated that the effects of ATRA depend on the relative levels of TR3, RARalpha and RXRalpha expression in cancer cells. In ATRA-induced MCF-7 cells, highly expressed TR3 favours the formation of TR3/RXRalpha and promotes the TR3/RXRalpha signalling pathway causing apoptosis; while in ATRA-induced MGC80-3 cells, high expression of RARalpha favours the formation of RARalpha/RXRalpha and promotes the RXRalpha/RARalpha signalling pathway in mediating cell cycle regulation. In conclusion, these results reveal the novel mechanism that cellular expression and location of protein is associated with diverse signalling transduction pathways and the resultant physiological process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14592536     DOI: 10.1016/s1357-2725(03)00143-2

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  6 in total

1.  A novel all-trans retinoic acid derivative inhibits proliferation and induces differentiation of human gastric carcinoma xenografts via up-regulating retinoic acid receptor β.

Authors:  Jing Ju; Nan Wang; Xinqun Wang; Feihu Chen
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

2.  HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.

Authors:  L Zhou; V R Ruvolo; T McQueen; W Chen; I J Samudio; O Conneely; M Konopleva; M Andreeff
Journal:  Leukemia       Date:  2012-12-18       Impact factor: 11.528

3.  Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.

Authors:  Annika N Alexopoulou; Maria Leao; Otavia L Caballero; Leonard Da Silva; Lynne Reid; Sunil R Lakhani; Andrew J Simpson; John F Marshall; A Munro Neville; Parmjit S Jat
Journal:  Breast Cancer Res       Date:  2010-07-19       Impact factor: 6.466

4.  NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer.

Authors:  Yu Cheon Kim; Clara Yuri Kim; Ji Hoon Oh; Myoung Hee Kim
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

Review 5.  Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review.

Authors:  Damien Bouriez; Julie Giraud; Caroline Gronnier; Christine Varon
Journal:  Int J Mol Sci       Date:  2018-10-29       Impact factor: 5.923

Review 6.  Retinoic Acids in the Treatment of Most Lethal Solid Cancers.

Authors:  Lara Costantini; Romina Molinari; Barbara Farinon; Nicolò Merendino
Journal:  J Clin Med       Date:  2020-01-28       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.